pharma · Unresectable Hepatocellular Carcinoma (HCC) · Unexplained Recurrent Miscarriage and Recurrent Implantation Failure
Zenshine Pharmaceuticals
Nanjing Zenshine Pharmaceuticals
Zenshine Pharmaceuticals trial registry — 8 ClinicalTrials.gov studies with program phase, status, and indication context.
CN HQ
2018 Founded
12 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Founded
- 2018
- Employees
- 12
- Programs
- 8
- Drugs
- 17
- Patents
- 0
Zenshine Pharmaceuticals clinical trials
Registry index of 8 ClinicalTrials.gov studies linked to Zenshine Pharmaceuticals programs — each row shows trial ID, program name, phase, status, and indication.
Zenshine Pharmaceuticals trial registry — 8 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Zenshine Pharmaceuticals.
-
TQB2101 for Injection — Phase 1
Clinical update -
RJK-RT2831 dose-escalation phase Ia — Phase 1
Clinical update -
Pre-operative chemotherapy — Phase 2
Clinical update -
Normal Saline — Approved
Clinical update -
low-dose lymphocyte immunotherapy — Phase 2
Clinical update -
Camrelizumab Plus Apatinib — Phase 2
Clinical update -
Rezvilutamide — Phase 2
Clinical update -
S-ketamine — Unknown
Clinical update
Trial registry
-
CT.gov ↗ - NCT03081325CT.gov ↗
low-dose lymphocyte immunotherapy
Unexplained Recurrent Miscarriage and Recurrent Implantation Failure
-
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗